Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule.

Basappa, Sugahara K, Thimmaiah KN, Bid HK, Houghton PJ, Rangappa KS.

PLoS One. 2012;7(8):e39444. doi: 10.1371/journal.pone.0039444. Epub 2012 Aug 15. Erratum in: PLoS One. 2012;7(10):doi/10.1371/annotation/a685ce21-d7a1-4a5b-8fe8-734a071d53cd.

2.
3.

A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-α.

Basappa, Murugan S, Kavitha CV, Purushothaman A, Nevin KG, Sugahara K, Rangappa KS.

Cancer Lett. 2010 Nov 28;297(2):231-43. doi: 10.1016/j.canlet.2010.05.016. Epub 2010 Jun 17.

PMID:
20831981
4.

Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.

Nishiguchi KM, Kataoka K, Kachi S, Komeima K, Terasaki H.

PLoS One. 2010 Oct 20;5(10):e13493. doi: 10.1371/journal.pone.0013493.

5.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.

Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.

7.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.

8.

Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.

Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH.

Glycobiology. 2009 Mar;19(3):229-39. doi: 10.1093/glycob/cwn114. Epub 2008 Oct 30.

9.

Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.

Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, Yang DP, Chen YL, Shen JG, Chen JP.

Breast Cancer Res Treat. 2012 Aug;134(3):943-55. doi: 10.1007/s10549-012-1977-9. Epub 2012 Feb 21.

10.

A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.

Tseng FJ, Chen YC, Lin YL, Tsai NM, Lee RP, Chung YS, Chen CH, Liu YK, Huang YS, Hwang CH, Lai YK, Liao KW.

Cancer Biol Ther. 2010 Nov 1;10(9):865-73. doi: 10.4161/cbt.10.9.13230. Epub 2010 Nov 1.

PMID:
20818186
11.

Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.

Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.

Life Sci. 2006 Nov 17;79(25):2370-81. Epub 2006 Aug 16.

PMID:
16959272
12.
13.

A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155.

Ueda Y, Yamagishi T, Samata K, Ikeya H, Hirayama N, Takashima H, Nakaike S, Tanaka M, Saiki I.

Mol Cancer Ther. 2003 Nov;2(11):1105-11.

14.

Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1.

Lake AC, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret GY, Letourneur D.

J Biol Chem. 2006 Dec 8;281(49):37844-52. Epub 2006 Oct 6.

15.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

16.

VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.

Ueda Y, Yamagishi T, Ikeya H, Hirayama N, Itokawa T, Aozuka Y, Samata K, Nakaike S, Tanaka M, Ono M, Saiki I.

Anticancer Res. 2004 Sep-Oct;24(5A):3009-17.

17.

HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model.

Lee TY, Folkman J, Javaherian K.

PLoS One. 2010 Apr 1;5(4):e9945. doi: 10.1371/journal.pone.0009945.

18.

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.

LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.

Angiogenesis. 2009;12(3):287-96. doi: 10.1007/s10456-009-9151-7. Epub 2009 Jun 21.

PMID:
19544081
19.

Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vitro.

Zhang W, Lu Y, Xu B, Wu J, Zhang L, Gao M, Zheng S, Wang A, Zhang C, Chen L, Lei N.

Cancer Biol Ther. 2009 Aug;8(15):1489-99. Epub 2009 Aug 8.

PMID:
19483477
20.

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.

Cancer Res. 2004 May 15;64(10):3586-92.

Items per page

Supplemental Content

Write to the Help Desk